Hydrodissection as a Treatment for Carpal Tunnel Syndrome

Overview

About this study

This is a pilot study designed to acquire data on the added value of hydrodissection when using a corticosteroid injection as a treatment for patients with carpal tunnel syndrome. Hydrodissection is part of a standard clinical care injection under ultrasound guidance in which the fluid is used to separate the nerve from surrounding structures.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

Inclusion Criteria:

  • Clinical CTS diagnosis with indication for steroid injection as determined by attending physician (if both hands are involved, only the side with the most severe CTS as indicated by electromyography (EMG) will be included); AND
  • Adult men and women between ages 21 and 80; AND
  • No more than moderate severity as indicated by EMG; AND
  • Symptoms of numbness or tingling for at least 4 weeks in the median nerve distribution area; AND
  • Classic or probable carpal tunnel syndrome on Katz-Stirrat hand diagram; AND
  • Ability to complete English-language questionnaires and clinical evaluations; AND
  • Is reachable by phone for the follow up contact.

Exclusion Criteria:

Exclusion criteria are largely based on the premises of only including patients with idiopathic carpal tunnel syndrome without expected interferences of the acquisition of the ultrasound images or corticosteroid treatment.

  • Previous Carpal Tunnel Release (CTR) or other volar wrist surgery on the study hand OR known tumor/mass OR deformity of the study hand/wrist; OR
  • Previous history of steroid injection into carpal tunnel; OR
  • Currently taking a steroid medication either regularly or on an as needed basis; OR
  • Any of the following clinical diagnoses or conditions: Cervical radiculopathy; rheumatoid or other inflammatory arthritis, including gout; osteoarthritis in the wrist; renal failure; sarcoidosis; peripheral nerve disease; diabetes, uncontrolled thyroid disease or other metabolic disorder; pregnancy; amyloidosis; or major trauma (fractures or complete ligamentous tears) to the ipsilateral arm; OR
  • Prisoners, institutionalized individuals, or others who may be considered vulnerable populations, such as individuals with dementia.

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Peter Amadio, M.D.

Contact us for the latest status

Contact information:

Jonathan Furuseth

127or7736470

Furuseth.Jonathan@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20396297

Mayo Clinic Footer